Kymera Therapeutics, Inc. - Common Stock (KYMR)

CUSIP: 501575104

Q1 2024 13F Holders as of 31 Mar 2024

Holder snapshot 7 signals
Share change
+6,779,105
Put/Call ratio
24%
SEC-reported price per share
$40.20
Number of holders
161
Value change
+$296,832,171
Number of buys
97
Open additional details 1 more signal available
Number of sells
58
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
82,580,091

Security key

501575104

Report period

Q1 2024

Institutions

161

Top holders

10

Ownership snapshot

Top reported holders of KYMR - Kymera Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Atlas Venture Fund X, L.P.
Disclosed value leader
Atlas Venture Fund X, L.P.
Comparable rows
0/15
Latest evidence
11 Mar 2024
3/4/5 13F Highest disclosed value: $235,830,130 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Atlas Venture Fund X, L.P. has the largest disclosed position value at $235.83M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Atlas Venture Fund X, L.P.'s linked filing trail.
Disclosed position value Top 5
Atlas Venture Fund X, L.P. $235.83M
ATLAS VENTURE ASSOCIATES X, L.P. $173.16M
BAKER BROS. ADVISORS LP $152.66M
Atlas Venture Life Science Adviso... $149.15M
PRICE T ROWE ASSOCIATES INC /MD/ $135.85M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Atlas Venture Fund X, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$235,830,130
5,504,905 shares
— 11 Mar 2024
ATLAS VENTURE ASSOCIATES X, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$173,161,222
5,763,012 shares
— 11 Aug 2021
BAKER BROS. ADVISORS LP
13F
Company
13F
—
denominator unverified
$152,656,327
5,995,928 shares
— 31 Dec 2023
Atlas Venture Life Science Advisors, LLC
13F
Company
13F
—
denominator unverified
$149,151,351
5,858,262 shares
— 31 Dec 2023
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
13F
—
denominator unverified
$135,848,000
5,335,712 shares
— 31 Dec 2023
BVF INC/IL
13F
Company
13F
—
denominator unverified
$131,419,453
5,161,801 shares
— 31 Dec 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
161
Shares
67,207,302
Rows available
161
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders
161
Q1 2024 holders
161
Holder diff
0
Investor Q1 2024 Shares Q1 2024 Shares Share Diff Share Chg % Q1 2024 value Q1 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .